Bayer to let go of 90 workers at NJ site

上市批准引进/卖出
Bayer will be letting go of 90 employees at its Whippany, New Jersey site, the company revealed this week in a Worker Adjustment and Retraining Notification (WARN).
Bayer opened its U.S. headquarters on the 94-acre campus in Whippany back in 2013. The headquarters consolidated Bayer HealthCare’s operations that had previously been spread across Morristown, Montville, and Wayne, New Jersey, as well as Tarrytown, New York, into one campus.
The layoff news comes just a few months after the drugmaker announced a significant workforce reduction at its German sites. At the time, the company also unveiled a new global operating model, "Dynamic Shared Ownership," which has the aim of “improving agility and operational efficiency by reducing hierarchies, eliminating bureaucracy, and expediting decision-making processes.”
Earlier this month, Bayer secured exclusive rights to commercialize BridgeBio's promising heart disease drug, acoramidis, in Europe, as the drug awaits approval from regulators. Acoramidis, an experimental treatment for the rare and deadly heart condition ATTR-CM, could significantly impact heart failure outcomes. Bayer's deal with BridgeBio includes payments up to $310 million, covering initial, milestone payments, plus royalties.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。